Tridek-One Closes A €16M Financing Round Led By Pureos Bioventures

Sep 15, 2022•about 3 years ago

Amount Raised

€16 Million

ParisBiotechnologyHealth Care

Description

Tridek-One SAS, a biotech start-up specialised in the research and development of CD31 agonists to restore the immune balance, has closed a €16 million ($16.1m) financing round led by the Swiss VC Pureos Bioventures.

Company Information

Company

Tridek-One

Location

Paris, Ile De France, France

About

Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, with the support of the funds Advent France Biotechnology, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. Tridek-One has announced a 3M€ funding supported by two venture funds, Advent France Biotechnology and Advent Life Sciences (UK).

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Tridek-One Closes A €16M Financing Round Led By Pureos Bioventures

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information